GC
XLRN

Guggenheim Capital’s Acceleron Pharma XLRN Stock Holding History

Guggenheim Capital’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,052
Closed -$3.45M – 2290
2021
Q3 		$3.45M Sell
20,052
-513
-2% -$67.1K 0.02% 809
2021
Q2 		$2.58M Buy
20,565
+516
+3% +$65.1K 0.02% 951
2021
Q1 		$2.72M Sell
20,049
-911
-4% -$118K 0.02% 880
2020
Q4 		$2.68M Sell
20,960
-6,815
-25% -$799K 0.02% 849
2020
Q3 		$3.13M Sell
27,775
-5,836
-17% -$581K 0.02% 714
2020
Q2 		$3.2M Buy
+33,611
New +$3.24M 0.02% 695
2017
Q4 		– Sell
-65,051
Closed -$2.43M – 2847
2017
Q3 		$2.43M Sell
65,051
-1,423
-2% -$49.4K 0.01% 1518
2017
Q2 		$2.02M Sell
66,474
-1,708
-3% -$49.5K 0.01% 1622
2017
Q1 		$1.8M Buy
68,182
+1,776
+3% +$46.8K ﹤0.01% 1738
2016
Q4 		$1.7M Buy
+66,406
New +$2.1M ﹤0.01% 1804
2014
Q4 		– Sell
-35,038
Closed -$1.06M – 3139
2014
Q3 		$1.06M Sell
35,038
-2,514
-7% -$70.8K ﹤0.01% 2194
2014
Q2 		$1.28M Buy
+37,552
New +$1.26M ﹤0.01% 2130

Guggenheim Capital's XLRN Position: Q4 2021 in Review

Guggenheim Capital sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 20,052 shares — an estimated $3.45M sold.

Guggenheim Capital first reported a position in XLRN in Q2 2014 and held it in 12 quarters. The position peaked at $3.45M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Guggenheim Capital reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Guggenheim Capital sold 20,052 Acceleron Pharma shares in Q4 2021, an estimated $3.45M.
  • Guggenheim Capital first reported a position in Acceleron Pharma in Q2 2014 and held it in 12 quarters.
  • Guggenheim Capital's Acceleron Pharma position peaked at $3.45M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Guggenheim Capital's 13F filing for Q4 2021, filed 14 Feb 2022.